Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Neoplasm”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT00772798
What this trial is testing

A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Herlev Hospital 70
Early research (Phase 1)Study completedNCT03371004
What this trial is testing

DM-CHOC-PEN Plus Radiation for Brain Tumors

Who this might be right for
Advanced Cancer
DEKK-TEC, Inc. 19
Testing effectiveness (Phase 2)Ended earlyNCT04294784
What this trial is testing

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Who this might be right for
Gastric CancerGastroEsophageal Cancer
Huazhong University of Science and Technology 58
Testing effectiveness (Phase 2)Study completedNCT00072852
What this trial is testing

Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

Who this might be right for
Breast Neoplasms
Pfizer 134
Testing effectiveness (Phase 2)Study completedNCT00230126
What this trial is testing

OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Ohio State University Comprehensive Cancer Center 57
Large-scale testing (Phase 3)Active Not RecruitingNCT04208178
What this trial is testing

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Who this might be right for
Advanced HER2+Breast Cancer
Novartis Pharmaceuticals 19
Large-scale testing (Phase 3)Study completedNCT02234115
What this trial is testing

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

Who this might be right for
Prostatic Neoplasms
Foresee Pharmaceuticals Co., Ltd. 137
Testing effectiveness (Phase 2)Study completedNCT01222936
What this trial is testing

LBH Phase II in Small Cell Lung Cancer (SCLC)

Who this might be right for
Small Cell Lung Carcinoma
Southern Europe New Drug Organization 21
Testing effectiveness (Phase 2)Study completedNCT00318136
What this trial is testing

Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)

Who this might be right for
Non-small Cell Lung Cancer
Genentech, Inc. 47
Not applicableEnded earlyNCT00727532
What this trial is testing

Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Who this might be right for
Hereditary Clear Cell Renal Cell CarcinomaKidney Cancer
Northwestern University 9
Early research (Phase 1)Study completedNCT00027898
What this trial is testing

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 27
Testing effectiveness (Phase 2)UnknownNCT05527821
What this trial is testing

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Who this might be right for
Unresectable Advanced Solid TumorsBiliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 36
Early research (Phase 1)Study completedNCT02646748
What this trial is testing

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Who this might be right for
Colorectal Cancer (CRC)Endometrial CancerMelanoma+8 more
Incyte Corporation 159
Early research (Phase 1)Active Not RecruitingNCT03502733
What this trial is testing

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Who this might be right for
LymphomaMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI) 64
Early research (Phase 1)Looking for participantsNCT06883149
What this trial is testing

PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor

Who this might be right for
Solid TumorAdult
Chinese PLA General Hospital 25
Early research (Phase 1)Study completedNCT04857138
What this trial is testing

Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumors
Hoffmann-La Roche 80
Early research (Phase 1)Study completedNCT04975958
What this trial is testing

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Who this might be right for
Locally Advanced Solid Tumor
Adlai Nortye Biopharma Co., Ltd. 47
Testing effectiveness (Phase 2)UnknownNCT05117658
What this trial is testing

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 83
Testing effectiveness (Phase 2)Looking for participantsNCT05599048
What this trial is testing

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Robert Bok, MD, PhD 65
Not applicableUnknownNCT03566576
What this trial is testing

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Fujian Cancer Hospital 18
Next Page